Арилжаа Assembly Biosciences, Inc. - ASMB CFD

Арилжааны нөхцөл

• Төрөл: CFD
• Спред: 0.42
• Лонг позицын шөнийн санхүүжилтийн тохируулга: -0.02151%
• Шорт позицын нэг шөнийн санхүүжилтийн тохируулга: -0.00071%
• Шөнийн санхүүжилтийг тохируулах хугацаа: 21:00 (UTC)
• Валют: USD
• Арилжаалсан доод хэмжээ: 1
• Маржин: 5.00%
• Хөрөнгийн бирж: United States of America
• Арилжааны шимтгэл: 0%
• Баталгаат стопын шимтгэл: 1%

Гол үзүүлэлтүүд

• Өмнөх Хаах: 26.42
• Нээх: 27.5
• 1 жилийн өөрчлөлт: 161.68%
• Өдрийн диапазон: 26.71 - 27.74

Арилжаа Assembly Biosciences, Inc. - ASMB CFD

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, Ltd.; and Arbutus Biopharma Corporation, as well as strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. It also has a clinical collaboration agreement with Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.